Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · July 05, 2024

Subcutaneously Administered Tirzepatide vs Semaglutide for Adults With Type 2 Diabetes

Diabetologia

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetologia
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Diabetologia 2024 Jul 01;67(7)1206-1222, T Karagiannis, K Malandris, I Avgerinos, A Stamati, P Kakotrichi, A Liakos, D Vasilakou, N Kakaletsis, A Tsapas, E Bekiari

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading